Further clinical observation on tribendimidine against intestinal helminth infection and the new progress in laboratory study

Abstract

Tribendimidine is a new broad-spectrum anthelmintic agent developed in China. After tri-bendimidine enteric-coated tablet was approved by the Chinese State Food and Drug Administration in 2004, a phase Ⅳ clinical trial was carried out during 2006-2007. Through the treatment of the larger sample of patients with intestinal helminthiasis and various ages, including children, the efficacy of tribendimidine enteric-coated tablet against Ascaris lumbricoides infection and hookworm infection was further confirmed, when the drug was administered orally to the adults and children patients at a single dose of 400 rag and 200 mg, respectively, Tri-bendimidine was also showed promising efficacy against Enterobius vermicularis infection in children, In recent years, the results from the laboratory study and clinical trial indicate that tribendimidine exhibits promising effect against several species of trematodes, including Clonorchis sinensis, Opistorchis viverrini, Echinoswma ca-proni, Strongyloides spp. and Taenia spp.. This paper summarizes the new progress on tribendimidine re-search. Key words: Tribendimidine ; Chemotherapy ; Ascaris lumbridoides; Hookworm; Enterobius vermicularis ; Trematode; Taenia spp. ; Strongyloides spp.